publication venue for
- Artificial neural networks for simultaneously predicting the risk of multiple co‐occurring symptoms among patients with cancer. 10:989-998. 2021
- Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. 10:1212-1221. 2021
- The impact of routine Edmonton Symptom Assessment System (ESAS) use on overall survival in cancer patients: Results of a population‐based retrospective matched cohort analysis. 9:7107-7115. 2020
- Albert C. Broders, tumor grading, and the origin of the long road to personalized cancer care. 9:4490-4494. 2020
- Describing symptoms using the Symptom Screening in Pediatrics Tool in hospitalized children with cancer and hematopoietic stem cell transplant recipients. 7:1750-1755. 2018
- Treatment-related mortality in newly diagnosed pediatric cancer: a population-based analysis. 7:707-715. 2018
- Two BRM promoter insertion polymorphisms increase the risk of early‐stage upper aerodigestive tract cancers. 3:426-433. 2014
- Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration‐resistant prostate cancer treated with custirsen. 2:468-477. 2013
- A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion. 2:334-342. 2013
- Phase II study of TAS ‐106 in patients with platinum‐failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. 2:351-359. 2013